Divalproex sodium (Depakote ER)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Migraine, Epilepsy, Bipolar Disorder, Absence Seizures, Focal Onset Seizures

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Latest reported trial: NCT00060905 · Phase 3 · met primary endpoint · grade pending

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (8)
Bipolar Disorder
NCT00183443 · Palo Alto Veterans Institute for Research
2005-02 – 2010-11 · Bipolar Disorder, Schizophrenia
What this study did
NCT00194116 · University Hospitals Cleveland Medical Center
2004-09 – 2008-02 · Bipolar Disorder
What this study did
Migraine
Phase 2 (3)
Epilepsy
NCT00646711 · Abbott
2003-02 – 2003-12 · Pediatric Epilepsy
What this study did
Other / comorbidity
NCT00073164 · Abbott
started 2003-07 · Schizophrenia
What this study did
NCT00204503 · The University of Texas Medical Branch, Galveston
2003-06 – 2005-05 · Bipolar I or II Depression and Alcohol Abuse or Dependence
What this study did
Phase 1 (5)
Bipolar Disorder
NCT01094249 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2009-02 – 2009-04 · Schizophrenia, Bipolar Disorder, Psychotic Disorders
What this study did
Epilepsy
NCT01060228 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2009-01 – 2009-02 · Schizophrenia, Epilepsy
What this study did
Other / comorbidity
NCT04902105 · Emalex Biosciences Inc.
2021-05-13 – 2021-07-06 · Drug Interaction
What this study did
NCT01581775 · Dr. Reddy's Laboratories Limited
2011-01 – 2011-03 · Healthy
What this study did
NCT01581788 · Dr. Reddy's Laboratories Limited
2011-01 – 2011-03 · Healthy
What this study did
Phase 4 (9)
Bipolar Disorder
NCT00579280 · University of South Florida
2007-07 – 2010-12 · Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
What this study did
NCT00203528 · Tuscaloosa Research & Education Advancement Corporation
2004-01 – 2007-02 · Substance Abuse, Bipolar Depression
What this study did
NCT00181727 · Massachusetts General Hospital
2004-01 – 2006-11 · Bipolar Disorder, Mania
What this study did
NCT00199966 · Medical College of Wisconsin
2003-12 – 2005-11 · Bipolar Disorder
What this study did
Epilepsy
NCT00207935 · Children's National Research Institute
2005-08 – 2007-03 · Epilepsy, Mental Retardation, Developmental Disabilities
What this study did
Other / comorbidity
NCT00186186 · Stanford University
2004-01 – 2009-01 · Depression, Bipolar
What this study did
NCT00211796 · Montefiore Medical Center
2005-04 – 2007-04 · Autism
What this study did
NCT00211250 · Joliet Center for Clinical Research
2005-07 – 2006-09 · Mood Disorder
What this study did
Early phase / not applicable (1)
Epilepsy
NCT00318929 · Virginia Commonwealth University
2006-04 – 2008-01 · Elderly, Epilepsy, Seizures
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (2)
Other / comorbidity
NCT00647712 · Mylan Pharmaceuticals Inc
2004-12 – 2004-12 · Healthy
What this study did
NCT00648076 · Mylan Pharmaceuticals Inc
2004-12 – 2004-12 · Healthy
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Absence Seizures: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Divalproex Sodium (Depakote ER): this drugApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.